RenovaCare Elects Alan L. Rubino to Chairman of the Board of Directors

Roseland, NJ – October 5, 2020 – RenovaCare, Inc. (Symbol: RCAR), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that Alan L. Rubino, Chief Executive Officer and President, has been elected to the additional role of Chairman of the Board of RenovaCare effective October 1, 2020.

RenovaCare to Present at BioNJ/JP Morgan/J&J BioPartnering Conference

Roseland, NJ – September 15, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company will present at the tenth annual BioPartnering Conference, hosted by BioNJ and co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, scheduled for October 6 – 7, 2020.

RenovaCare Receives FDA Conditional IDE Approval of CellMist™ System and SkinGun™ Device, Enabling Clinical Study for Safety and Feasibility

Roseland, NJ – August 11, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the US Food and Drug Administration (FDA) conditionally approved the Company’s Investigational Device Exemption (IDE) application to conduct a clinical trial to evaluate the safety and feasibility of autologous stem cells rendered by its CellMist™ System from donor skin and applied topically with the SkinGun™ spray device for treatment of burn wounds.

RenovaCare Launches R&D Innovation Center (Berlin) for Organ & Tissue Regeneration

Roseland, NJ – July 1, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced the official launch of its new RenovaCare R&D Innovation Center in Berlin, Germany, where the Company’s patented technologies for isolating and spraying self-donated stem cells to regenerate tissues and organs have been under development alongside new product initiatives.

RenovaCare Appoints Chief Medical Officer, Dr. Jo Ellen Schweinle, Former Sr. Medical Officer at U.S. Dept. of Health and Human Services

Roseland, NJ – June 10th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced the appointment of its first Chief Medical Officer, Jo Ellen Schweinle, MD.

RenovaCare Strengthens FDA Program with Leading U.S. Regulatory Group and Significant Investment

Roseland, NJ – May 28th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that it has expanded its engagement with MCRA, the leading U.S. regulatory group for medical devices and biologics, to continue to advance the Company’s FDA program.

RenovaCare Appoints Founding Director of BARDA Dr. Robin A. Robinson to Chief Scientific Officer

Roseland, NJ – May 26th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that its Vice President, Scientific Affairs, Dr. Robin A. Robinson will now serve in a new and expanded full-time role as the Company’s Chief Scientific Officer.

Spray-on Gene Therapy with RenovaCare SkinGun™ in New Study Underway at King’s College London

Roseland, NJ – March 30th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company’s novel SkinGun™ is now being used to apply regenerative cells in a preclinical study of new gene therapies, underway at King’s College London.  Researchers are using the SkinGun™ to ultra-gently spray gene-supplemented cells for accelerated wound healing in Recessive Dystrophic Epidermolysis Bullosa (RDEB), a debilitating skin disease which afflicts young children and leads to premature death.